Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced müllerian cancer: A pilot study

Clinical Imaging

Volumn 34, Issue 3, 2010, Pages 191-195

  Barlin, Joyce N ^a   Bristow, Robert E ^a   Bleich, Karen ^a   Giuntoli, Robert L ^a   Thompson, Sharon ^a   Diaz Montes, Teresa P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Computed tomographic peritoneography; Intraperitoneal chemotherapy; M llerian cancer

Indexed keywords

DISTRIBUTION INDEX; INTRAPERITONEAL; INTRAPERITONEAL CHEMOTHERAPY; PILOT STUDIES; TOMOGRAPHIC;

CHEMOTHERAPY;

PACLITAXEL;

ADVANCED CANCER; ADVANCED MULLERIAN CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC PERITONEOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; DISTRIBUTION VOLUME; HUMAN; LAPAROTOMY; LIVER CANCER; PRIORITY JOURNAL; RECTOSIGMOID SURGERY; SCORING SYSTEM; TREATMENT DURATION; UROGENITAL TRACT CANCER; UROLOGIC SURGERY;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MULLERIAN DUCTS; OVARIAN NEOPLASMS; PERITONEUM; PILOT PROJECTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77952790351     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2009.05.009     Document Type: Article

References (23)

1. Weisberger AS, Levine B, Storaasli JP Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955, 159(18):1704-1707.
2. Dedrick RL, Myers CE, Bungay PM, DeVita VT Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978, 62(1):1-11.
3. Markman M Intraperitoneal drug delivery of antineoplastics. Drugs 2001, 61(8):1057-1065.
4. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335(26):1950-1955.
5. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19(4):1001-1007.
6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354(1):34-43. Gynecologic Oncology Group.
7. National Cancer Institute Clinical announcement: intraperitoneal chemotherapy for ovarian cancer. January 4, 2006 http://wwwcancergov/newscenter/pressreleases/IPchemotherapyrelease.
8. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007, 109(4):692-702.
9. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol 1979, 133(2):221-223.
10. Twardowski ZJ, Tully RJ, Ersoy FF, Dedhia NM Computerized tomography with and without intraperitoneal contrast for determination of intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients. ASAIO Trans 1990, 36(2):95-103.
11. Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP, Curtin J, Schlaerth J Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol 1992, 3(2):149-154.
12. Hughes PM, Zammit-Maempel I, Murphy D Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer. Br J Radiol 1992, 65(772):295-297.
13. Yoonessi M, Abdel-Dayem HM, Shalaby OF The use of scintigraphic and contrast peritoneography in gynecologic malignancies. Diagn Gynecol Obstet 1982, 4(1):75-78.
14. Wahl RL, Gyves J, Gross BH, Cochran M, Juni JE, Arnstein NB, Lahti D, Ackermann RJ SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution. AJR Am J Roentgenol 1989, 152(6):1205-1210.
15. de Forni M, Boneu A, Otal P, Martel P, Shubinski R, Bugat R, Lucot H Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography. Bull Cancer 1993, 80(4):345-350.
16. Sugimura K, Okizuka H, Kaji Y, Ishida T, Iwanari O, Kitao M Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma. Clin Nucl Med 1994, 19(7):600-603.
17. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003, 13(Suppl 2):196-203.
18. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21(15):2849-2855. Gynecologic Oncology Group.
19. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J Clin Oncol 2003, 21(23):4350-4355.
20. Frasci G, Contino A, Iaffaioli RV, Mastrantonio P, Conforti S, Persico G Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol 1994, 52(2):154-160.
21. Giunta S, Venturo I, Mottolese M, Salzano M, Diotallevi F, Squillaci S, Bigotti A, Curcio CG, Atlante G, Natali PG Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology. Gynecol Oncol 1994, 53(1):103-108.
22. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, Spriggs DR, Barakat R Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001, 81(1):77-81.
23. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 1994, 4(10):1820-1826.